Cytokinetics’ Phase III Data Sets Up Cardiomyopathy Challenge to BMS 5/14/2024

AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Next-Gen Psychedelics for Psychiatric Disorders 5/14/2024

Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France 5/13/2024

Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts 5/13/2024

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy 5/13/2024

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs 5/13/2024

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy? 5/13/2024

Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market 5/13/2024

FDA Action Alert: Dynavax, Ascendis and BMS 5/13/2024

Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study 5/13/2024

Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials 5/13/2024

Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa... 6/5/2024

FDA Adcomm Votes Against Lykos’ MDMA-Assisted PTSD Therapy 6/5/2024

Viking Builds Case for NASH Hopeful With Histological Data 6/5/2024

Lilly’s Zepbound Wins NICE Backing for Obese Patients With Very High BMI 6/5/2024

Companies to Watch for Potential M&As in 2024 6/5/2024

The ABCs of Biopharma This Week: ASCO, BIO and Cancer 6/5/2024

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024

Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials 4/5/2024

Networking, ADCs and Early Science on the Agenda at AACR 2024 4/5/2024